Clavis Pharma hosts Capital Markets Day in Oslo
(Thomson Reuters ONE) -
Oslo, Norway, June 15, 2010
Clavis Pharma ASA (OSE: CLAVIS), the Norwegian cancer drug development company,
hosts its Capital Markets Day in Oslo on Wednesday 16 June, at 08:30 CET at the
Hotel Continental, Stortingsgt.24/26, Oslo. Registration and breakfast is from
08:00 CET.
The Capital Markets Day will be open to analysts, investors, press and other
interested parties.
The guest speakers for the event are:
· Professor Alan Burnett, Head of Haematology at the Department of
Medical Genetics, Haematology & Pathology at Cardiff University School of
Medicine, UK
· Patrick Mahaffy, CEO of Clovis Oncology, Inc.
· Dr. Tone Ikdahl, Head of Gastrointestinal and uro-oncology Unit at the
Department of Oncology, Oslo University Hospital
Additional speakers are members of Clavis Pharma's senior management team.
A webcast of the presentations will be available simultaneously at
www.clavispharma.com/webcast
To register for the webcast event, please use this URL:
http://w.on24.com/r.htm?e=219675&s=1&k=1652A9C4F2322B5FAEBF5D62250CFEEB
Please dial in 10 to 15 minutes prior to the scheduled start time on Wednesday
16 June at 08:30 CET.
For further information and detailed agenda see our webpage or contact:
Olav Hellebø
Chief Executive Officer
+47 24 11 09 50
olav.hellebo(at)clavispharma.com
Gunnar Manum
Chief Financial Officer
+47 24 11 09 71
+47 95 17 91 90 (mob)
gunnar.manum(at)clavispharma.com
Mark Swallow / Nina Enegren / David Dible
Citigate Dewe Rogerson
+44 207 282 2948
clavispharma(at)citigatedr.co.uk
About Clavis Pharma
Clavis Pharma ASA is a clinical stage oncology drug development company based in
Oslo, Norway with a portfolio of novel anti-cancer drugs in development. These
patented New Chemical Entities (NCEs) are novel, improved versions of
commercially successful drugs, made using Clavis Pharma's Lipid Vector
Technology (LVT) chemistry. Data generated suggests these potential breakthrough
products may offer improved efficacy and reduced side effects through enhanced
pharmacokinetic properties, greater tissue penetration, altered metabolism and,
in certain cases, additional modes of action.
Clavis Pharma's has several drug candidates in formal development studies:
· Elacytarabine, an improved form of Ara-C, a leukaemia drug - about to
commence a Phase III randomized, controlled registration study in late-stage
acute myeloid leukaemia;
· Intravenous CP-4126, an improved version of gemcitabine - currently in
a Phase II comparative study with gemcitabine for the treatment of pancreatic
cancer;
· CP-4200, an azacitidine derivative - in preclinical development for
myelodysplastic syndrome (MDS), often a precursor to myeloma or leukaemia.
Clavis Pharma intends to commercialise its products through strategic alliances
and partnerships with experienced oncology businesses and, where and when
commercially appropriate, by establishing its own sales and marketing
capabilities. CP-4126 is licensed to Clovis Oncology in the Americas and Europe.
Clavis Pharma has retained rights in other territories and an option to
co-promote CP-4126 in Europe.
The shares of Clavis Pharma ASA are listed on the Oslo Stock Exchange (ticker:
CLAVIS).
Disclaimer
This news release contains forward-looking statements and forecasts based on
uncertainty, since they relate to events and depend on circumstances that will
occur in the future and which, by their nature, will have an impact on results
of operations and the financial condition of Clavis Pharma. There are a number
of factors that could cause actual results and developments to differ materially
from those expressed or implied by these forward-looking statements. Theses
factors include, among other things, risks associated with technological
development, the risk that research & development will not yield new products
that achieve commercial success, the impact of competition, the ability to close
viable and profitable business deals, the risk of non-approval of patents not
yet granted and difficulties of obtaining relevant governmental approvals for
new products.
No expressed or implied representations or warranties are given concerning
Clavis Pharma or the accuracy or completeness of the information provided
herein, and no claims shall be made by the recipient hereof by virtue of this
News Announcement or the information contained herein.
Clavis Pharma(TM) is a registered trademark of Clavis Pharma ASA.
This information is subject of the disclosure requirements acc. to §5-12 vphl
(Norwegian Securities Trading Act)
This information is subject of the disclosure requirements acc. to §5-12 vphl
(Norwegian Securities Trading Act)
[HUG#1423975]
Unternehmensinformation / Kurzprofil:
Datum: 15.06.2010 - 11:23 Uhr
Sprache: Deutsch
News-ID 22434
Anzahl Zeichen: 0
contact information:
Town:
Oslo
Kategorie:
Business News
Diese Pressemitteilung wurde bisher 218 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"Clavis Pharma hosts Capital Markets Day in Oslo"
steht unter der journalistisch-redaktionellen Verantwortung von
Clavis Pharma ASA (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
